Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Inclusion criteria

• Adults ≥18 years of age
• Documented diagnosis of POAG or OHT, in both eyes
• Willing and able to provide written informed consent

Exclusion criteria

• History of any form of glaucoma in either eye, other than POAG
• Subjects who are unwilling or unable to discontinue contact lens wear prior to and during study
• History of ocular trauma in either eye <6 months prior to Screening
• History of ocular infection or ocular inflammation in either eye <3 months prior to Screening
• History of chronic or recurrent severe inflammatory eye disease, any severe ocular pathology, or clinically relevant or progressive retinal diseases in either eye
• Clinically relevant, severe central visual field loss, or documented significant progression of a visual field defect within 6 months prior to Screening in either eye
• Use of any ocular hypertensive medications (if applicable), in either eye, during the washout period and for the duration of the study
• Use of any glucocorticoid medications <2 weeks prior to Screening and throughout the duration of the study
• Use of any medication or substance on a chronic basis which has not been taken at a stable dose for at least 30 days prior to Screening
• Use of any nondiagnostic, topical, ophthalmic preparations, in either eye, other than artificial tears
• The presence of any concurrent condition or clinically significant laboratory findings at Screening that may interfere with any aspect of safety, study conduct, or interpretation of results
• Women who are pregnant or breast feeding
• Inability or difficulty instilling eye drops